Incyte Reports 2017 Second-Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Incyte (INCY) Misses Q2 EPS by 3c, Sales Beat; Raises FY17 Jakafi Revenue Outlook
August 1, 2017 7:11 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $326.44 million versus the consensus estimate of $315.4 million.
Raises Jakafi net product revenues guidance for 2017 to $1.09-$1.112B versus $1.02-$1.07 billion... More
